These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 22160482)
21. Examination of CD302 as a potential therapeutic target for acute myeloid leukemia. Lo TH; Abadir E; Gasiorowski RE; Kabani K; Ramesh M; Orellana D; Fromm PD; Kupresanin F; Newman E; Cunningham I; Hart DNJ; Silveira PA; Clark GJ PLoS One; 2019; 14(5):e0216368. PubMed ID: 31075107 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609 [TBL] [Abstract][Full Text] [Related]
23. Live kinase B1 maintains CD34 Wang H; Wang X; Xin N; Qi L; Liao A; Yang W; Liu Z; Zhao C Mol Cell Biochem; 2017 Oct; 434(1-2):25-32. PubMed ID: 28397012 [TBL] [Abstract][Full Text] [Related]
24. Induction and Therapeutic Targeting of Human NPM1c Kaur M; Drake AC; Hu G; Rudnick S; Chen Q; Phennicie R; Attar R; Nemeth J; Gaudet F; Chen J J Immunol; 2019 Mar; 202(6):1885-1894. PubMed ID: 30710044 [TBL] [Abstract][Full Text] [Related]
25. Small molecule regulation of normal and leukemic stem cells. Fares I; Rivest-Khan L; Cohen S; Sauvageau G Curr Opin Hematol; 2015 Jul; 22(4):309-16. PubMed ID: 26049751 [TBL] [Abstract][Full Text] [Related]
26. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Plasilova M; Zivny J; Jelinek J; Neuwirtova R; Cermak J; Necas E; Andera L; Stopka T Leukemia; 2002 Jan; 16(1):67-73. PubMed ID: 11840265 [TBL] [Abstract][Full Text] [Related]
27. Decitabine enhances targeting of AML cells by CD34 Cany J; Roeven MWH; Hoogstad-van Evert JS; Hobo W; Maas F; Franco Fernandez R; Blijlevens NMA; van der Velden WJ; Huls G; Jansen JH; Schaap NPM; Dolstra H Blood; 2018 Jan; 131(2):202-214. PubMed ID: 29138222 [TBL] [Abstract][Full Text] [Related]
28. Bringing Leukemia Stem Cells into the Clinic. Wang JC Oncology; 2015; 89 Suppl 1():25-7. PubMed ID: 26551024 [TBL] [Abstract][Full Text] [Related]
29. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway. Yang Q; Chen K; Zhang L; Feng L; Fu G; Jiang S; Bi S; Lin C; Zhou Y; Zhao H; Chen XL; Fu G; Xu B Cancer Lett; 2019 Oct; 461():31-43. PubMed ID: 31301319 [TBL] [Abstract][Full Text] [Related]
30. Retroviral marking of acute myelogenous leukemia progenitors that initiate long-term culture and growth in immunodeficient mice. Ailles LE; Humphries RK; Thomas TE; Hogge DE Exp Hematol; 1999 Nov; 27(11):1609-20. PubMed ID: 10560908 [TBL] [Abstract][Full Text] [Related]
31. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo. Yang J; Ikezoe T; Nishioka C; Nobumoto A; Yokoyama A Int J Cancer; 2013 Oct; 133(8):1967-81. PubMed ID: 23564444 [TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia. Strese S; Hassan SB; Velander E; Haglund C; Höglund M; Larsson R; Gullbo J Oncotarget; 2017 Jan; 8(4):6341-6352. PubMed ID: 27974676 [TBL] [Abstract][Full Text] [Related]
33. Antiproliferative activity of kinetin riboside on HCT-15 colon cancer cell line. Rajabi M; Gorincioi E; Santaniello E Nucleosides Nucleotides Nucleic Acids; 2012; 31(6):474-81. PubMed ID: 22646087 [TBL] [Abstract][Full Text] [Related]
34. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Guzman ML; Yang N; Sharma KK; Balys M; Corbett CA; Jordan CT; Becker MW; Steidl U; Abdel-Wahab O; Levine RL; Marcucci G; Roboz GJ; Hassane DC Mol Cancer Ther; 2014 Aug; 13(8):1979-90. PubMed ID: 24934933 [TBL] [Abstract][Full Text] [Related]
35. Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. Risueño RM; Campbell CJ; Dingwall S; Levadoux-Martin M; Leber B; Xenocostas A; Bhatia M Blood; 2011 Jun; 117(26):7112-20. PubMed ID: 21562049 [TBL] [Abstract][Full Text] [Related]
37. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437 [TBL] [Abstract][Full Text] [Related]
38. Inhibition of CK2{alpha} and PI3K/Akt synergistically induces apoptosis of CD34+CD38- leukaemia cells while sparing haematopoietic stem cells. Cheong JW; Min YH; Eom JI; Kim SJ; Jeung HK; Kim JS Anticancer Res; 2010 Nov; 30(11):4625-34. PubMed ID: 21115916 [TBL] [Abstract][Full Text] [Related]
39. The effect of cantharidins on leukemic stem cells. Dorn DC; Kou CA; Png KJ; Moore MA Int J Cancer; 2009 May; 124(9):2186-99. PubMed ID: 19123473 [TBL] [Abstract][Full Text] [Related]
40. Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Muranyi AL; Dedhar S; Hogge DE Leuk Res; 2010 Oct; 34(10):1358-65. PubMed ID: 20193963 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]